Meriofert

Follicle-Stimulating Hormone (FSH) and Luteinising Hormone (LH), the active ingredient in Meriofert, is a gonadotropin presented as a sterile injectable solution for intramuscular or subcutaneous use. It is employed to stimulate follicular development and ovulation in women with infertility. GNH USA supplies Meriofert as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Meriofert is a gonadotropin used in reproductive medicine to address disorders of ovulation and to support assisted reproductive technologies. - Infertility due to anovulation: promotes follicular growth and estradiol production to enable ovulation. - Controlled ovarian stimulation for assisted reproductive technologies: provides coordinated FSH and LH activity to develop multiple mature follicles. - Induction of ovulation in women undergoing IVF: supports the final maturation of oocytes for retrieval.

Adverse reactions may occur with any gonadotropin therapy.

Common Side Effects: - Injection site pain or erythema: mild discomfort at the administration site. - Ovarian hyperstimulation syndrome (mild): abdominal bloating and mild discomfort. - Headache: transient tension‑type headache. - Nausea: mild, self‑limiting gastrointestinal upset.

Serious or Rare Side Effects: - Ovarian hyperstimulation syndrome (severe): rapid weight gain, ascites, or respiratory distress. - Thromboembolic events: rare clot formation requiring urgent medical attention. - Allergic reaction: rash, urticaria, or anaphylaxis. - Ectopic pregnancy: rare occurrence following assisted reproduction.

Before initiating therapy, clinicians should evaluate patient suitability and monitor response. - Baseline ovarian assessment: perform ultrasound to estimate follicle count. - Monitor estradiol levels: adjust dosing based on serum concentrations. - Watch for signs of OHSS: educate patients on symptoms requiring prompt care. - Contraindications: avoid in known hypersensitivity to gonadotropins or active ingredients. - Storage: Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Meriofert may interact with other medications that influence ovarian response or coagulation.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased risk of bleeding with severe OHSS. - GnRH antagonists used concurrently without proper protocol: may blunt intended ovarian stimulation.

Moderate Interactions (Monitor Closely): - Oral contraceptives: may require a washout period before initiating therapy. - Thyroid hormone replacement: altered metabolism may affect ovarian response. - Corticosteroids: may mask early signs of OHSS. - Dopamine agonists: can affect prolactin levels influencing follicular dynamics.